CAR-T Therapy: Re-training the Immune System

CAR-T therapy is an advanced cancer treatment that uses a patient's own immune cells to fight cancer. In this approach, doctors collect T cells from the patient, modify them in a laboratory so they can recognise cancer cells, and then return them to the body. Once infused, these re-trained immune cells actively seek out and destroy cancer cells.

This treatment has already shown strong results in certain blood cancers, especially in patients whose disease has returned after standard treatments. For some conditions such as specific lymphomas and multiple myeloma, CAR-T therapy has offered new hope where options were previously limited. However, it is not yet used for all blood cancers. In acute myeloid leukaemia, for example, cancer cells closely resemble healthy bone marrow cells, making it difficult to target the disease without harming normal blood production.

Researchers are also exploring the use of CAR-T therapy for solid tumours, but progress is slower. Solid cancers can weaken immune responses, making treatment more complex. Ongoing clinical trials aim to improve the safety and effectiveness of CAR-T therapy, with the goal of making this personalised treatment available to more patients in the future.